Marine Biotechnology Market To Reach USD 13.3 Billion By 2032, Says DataHorizzon Research
May 04, 2024 03:50 ET
|
DataHorizzon Research
Fort Collins, Colorado, May 04, 2024 (GLOBE NEWSWIRE) -- The advantages of marine biotechnology encourage industry development. Marine biotechnology encompasses a wide array of applications,...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against HireRight, Doximity, Global Cord, and Lincoln Innovations and Encourages Investors to Contact the Firm
May 03, 2024 21:00 ET
|
Bragar Eagel & Squire
NEW YORK, May 03, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of...
BetterLife Announces Intent to Complete Private Placement of Units
May 03, 2024 18:00 ET
|
BetterLife Pharma Inc.
VANCOUVER, British Columbia, May 03, 2024 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on...
Compass Pathways to announce first quarter financial results on May 8, 2024
May 03, 2024 16:58 ET
|
Compass Pathways
LONDON, May 03, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health,...
Vision Sensing Acquisition Corp. Announces Payment of Fee to Extend Period to Consummate Initial Business Combination to June 3, 2024
May 03, 2024 16:30 ET
|
Vision Sensing Acquisition Corp.
Vision Sensing Acquisition Corp. Announces Payment of Fee to Extend Period to Consummate Initial Business Combination to June 3, 2024
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 03, 2024 16:30 ET
|
Dianthus Therapeutics, Inc.
NEW YORK and WALTHAM, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (“Dianthus”), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody...
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 03, 2024 16:05 ET
|
Taysha Gene Therapies, Inc.
DALLAS, May 03, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the...
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
May 03, 2024 16:01 ET
|
Verve Therapeutics
BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing...
Correction: Final Results
May 03, 2024 13:10 ET
|
Octopus Titan VCT plc
This announcement replaces the Final Results announcement released at 18:00 on 24 April 2024 which included an incorrect reference to the dividend being paid on 24 May 2024 to shareholders on the...
TAR-200 monotherapy shows greater than 80 percent complete response rate in patients with high-risk non-muscle-invasive bladder cancer
May 03, 2024 11:53 ET
|
Janssen Cilag International NV
New data from Phase 2b SunRISe-1 study show rapid achievement of complete response (CR) with 98 percent achieving a CR within 12 weeks1 TAR-200 provides durable CRs in patients with Bacillus...